louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04723459: Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff
Official title: Nano-Ivermectin Impregnated Masks Versus Ordinary Surgical Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Covid-19
Keywords: Covid-19
antiviral mask
nano ivermectin
Lead sponsor: South Valley University
Sponsor class: OTHER
First posted: 2021-01-25
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Sequential Assignment
Primary purpose: PREVENTION

Brief summary: Antiviral efficacy of Ivermectin against Covid-19 in vitro was stated by many stusies all over the world with decreased effecacy in vivo so ,usage of masks impregnated into nano Ivermectin solution will theoretically increase the protective action of the ordinary masks

Detailed description: Antiviral effecacy of Ivermectin against Covid-19 in vitro was stated by many stusies all over the world with decreased effecacy in vivo so ,usage of masks impregnated into nano Ivermectin solution will theoretically increase the protective action of the ordinary masks this study is a trial for evaluation of adding a proved antiviral material to the mask and to compare between the protective value of this mask and the ordinary one.

Eligibility criteria: Inclusion Criteria:

* health care personells and family contact of confirmed COVID-19 cases.

Exclusion Criteria:

* refusal of participate to use the masks.
* pregnancy or lactation known hypersensitivity to ivermectin.

Primary outcomes:
measure: Number of persons in each group who Complain of any suspected Symptoms
timeFrame: within 14 days after enrollement
Secondary outcomes:
measure: Number of persons in each group who are diagnosed as COVID-19 patients
timeFrame: within 21 days after enrollement
Other outcomes:
Locations:
city: Qina
country: Egypt
facility: Zaky Aref
Study officials:
References:
Clinical trial NCT03571659: Comparison of Different Fluence Settings for Yellow Subthreshold Laser Treatment in Diabetic Macular Edema
Official title: To Assess the Safety and Efficacy of Two Subthreshold Parameters (5% and 15% Duty Cycle (DC)) Compared to Standard ETDRS (Early Treatment of Diabetic Retinopathy Study) Continuous Wave (CW) Laser
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetic Retinopathy
Lead sponsor: L.V. Prasad Eye Institute
Sponsor class: OTHER
First posted: 2018-06-27
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Asian

Brief summary: To assess the safety and efficacy of two subthreshold parameters (5% and 15% duty cycle (DC)) compared to standard ETDRS (early treatment of diabetic retinopathy study) continuous wave (CW) laser

Detailed description: Test burn up to barely visible burn with micropulse laser, then reduce the power by 70% and perform laser with various DC (5%, 15%, cw) as per the group.

Focal to Mas+ confluent burns to areas of diffuse leakage

Eligibility criteria: Inclusion Criteria:

* Eyes with DME (center or non-center involving) with \<350 microns central retinal thickness

Exclusion Criteria:

* Subfoveal exudates, history of VR surgery, history of macular laser

Primary outcomes:
measure: 1. Decrease in number of leaking Mas on FFA 2. Decrease in diffuse leakage on FFA
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Chhablani J, Alshareef R, Kim DT, Narayanan R, Goud A, Mathai A. Comparison of different settings for yellow subthreshold laser treatment in diabetic macular edema. BMC Ophthalmol. 2018 Jul 11;18(1):168. doi: 10.1186/s12886-018-0841-z.
Clinical trial NCT02139059: Delayed or Direct Ureteroscopy in the Treatment of Pediatric Calcular Anuria
Official title: Staged Ureteroscopy After Initial Urinary Drainage Versus Direct Ureteroscopy in the Treatment of Pediatric Obstructive Calcular Anuria
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Renal Failure
Anuria
Obstructive Uropathy
Ureteric Stones
Keywords: anuria
children
ureteroscopy
initial urinary drainage
ureteric stones
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2014-05-15
Enrollment: 50
Sex: ALL
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare staged ureteroscopy following initial urinary drainage versus direct ureteroscopy without initial urinary drainage in the treatment of obstructive calcular anuria with acute renal failure in children.

Detailed description: To compare staged ureteroscopy following initial urinary drainage and stabilization of renal functions using percutaneous nephrostomy or double J stent versus direct ureteroscopy without initial urinary drainage in the treatment of obstructive calcular anuria with acute renal failure due to ureteric calculi in children.

Eligibility criteria: Inclusion Criteria:

* children ≤12 years old presenting with Obstructive Anuria and Acute Renal Failure due to bilateral ureteric stones suitable for ureteroscopy.

Exclusion Criteria:

* Fever, pyonephrosis or sepsis.
* unstable patients are stabilized first by dialysis.

Primary outcomes:
measure: Return to normal creatinine
timeFrame: 1 week
measure: stone free status
timeFrame: 1 week
measure: operative and early post operative complications
timeFrame: 1 week
Secondary outcomes:
measure: ureteric stricture
timeFrame: 6 months
measure: period to reach stone free status bilaterally
timeFrame: 6 months
measure: number of times of exposure to general anesthesia
timeFrame: 6 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University Hospitals
city: Cairo
country: Egypt
facility: Cairo University Hospitals
Study officials:
affiliation: Cairo University
name: Mohammed S ElSheemy, A professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04005859: Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane
Official title: Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Colorectal Disorders
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2019-07-02
Enrollment: 61
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the analgesic impact of intravenous perioperative lidocaine infusion with preoperative liposomal bupivacaine TAP block in colorectal surgery. This is to be integrated into the standard ERAS protocol currently utilized at Carolinas Medical Center. Primary endpoints will be postoperative pain as measured by verbal rate scale (VRS), postoperative morphine equivalents utilized per day, and over 30 days. Secondary endpoints will include date of ambulation, return of bowel function (first flatus), tolerance of goal diet, incidence of post-operative nausea and vomiting during hospital stay, length of stay (hospital and PACU), post-operative morbidity (Clavien-Dindo, related to both anesthesia and surgery), cost of hospitalization (operative, PACU, postoperative stay, and total) and quality of life on follow up.


Eligibility criteria: Inclusion Criteria:

* Age 18-75 years
* Elective laparoscopic colorectal surgery
* ASA I-III

Exclusion Criteria:

* Contraindication to Na Channel Blocker
* Chronic Opioid use
* Liver dysfunction
* Renal insufficiency
* Epilepsy
* Psychomotor retardation
* BMI \>40
* Sleep Apnea
* Cardiac Rhythm Disorders
* Planned open or concomitant procedure

Primary outcomes:
measure: Verbal Pain Scale (VRS) - 4 Week Post-op
timeFrame: Single VRS assessed at 4-week post-op visit (or phone call)
Secondary outcomes:
Other outcomes:
Locations:
city: Charlotte
country: United States
facility: Atrium Health - Carolinas Medical Center
state: North Carolina
Study officials:
affiliation: Wake Forest University Health Sciences
name: Kevin Kasten, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00619359: Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
Official title: A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intravenous MK-0517 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Cisplatin Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chemotherapy-Induced Nausea and Vomiting (CINV)
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2008-02-21
Enrollment: 2322
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin chemotherapy.


Eligibility criteria: Inclusion Criteria:

* Patient is male or female and is at least 18 years of age; scheduled to receive his or her first course of cisplatin chemotherapy at a dose of 70 mg/m2 or higher; predicted life expectancy of 3 months or greater
* Patient is post menopausal or, if premenopausal, must use double-barrier contraception

Exclusion Criteria:

* Patient has symptomatic primary or metastatic CNS malignancy
* Patient has received or will receive Radiation therapy to the abdomen or pelvis in the week prior to Treatment Day 1 though Day 6
* Patient has vomited in the 24 hours prior to treatment Day 1
* Patient has an active infection; Patient uses illicit drugs or has current evidence of alcohol abuse
* Patient is pregnant or breast feeding

Primary outcomes:
measure: A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin).
timeFrame: Overall (in the 120 hours following initiation of cisplatin chemotherapy).
Secondary outcomes:
measure: A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin).
timeFrame: Delayed phase (25 to 120 hours following initiation of cisplatin).
measure: No Vomiting Overall (in the 120 Hours Following Initiation of Cisplatin)
timeFrame: Overall (the 120 hours following initiation of cisplatin chemotherapy)
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011 Apr 10;29(11):1495-501. doi: 10.1200/JCO.2010.31.7859. Epub 2011 Mar 7.
Clinical trial NCT01882959: Radiofrequency Denervation for Reducing Chronic Pain: a Meta-analysis
Official title: Radiofrequency Denervation for Reducing Chronic Pain: a Meta-analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Neck Pain
Chronic Low Back Pain
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
First posted: 2013-06-21
Enrollment: 374
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with chronic neck or low back pain.

Brief summary: The meta-analysis of data obtained from randomized controlled trial on effectiveness of radiofrequency denervation on reducing chronic neck and low back pain.


Eligibility criteria: Inclusion Criteria:

* RCTs with pain VAS as outcome

Exclusion Criteria:

* None

Primary outcomes:
measure: Pain Visual Analogue Scale
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04736459: Pre-washing the Catheter With a Culture Medium Before Intrauterine Insemination
Official title: Does Pre-washing the Catheter With a Culture Medium Before Intrauterine Insemination Have an Effect on Pregnancy Rates?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Infertility
Keywords: intrauterine insemination, pre-washing catheter
Lead sponsor: Eskisehir Osmangazi University
Sponsor class: OTHER
First posted: 2021-02-03
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The aim of the study to evaluate the possible effect of washing the insemination catheters before intrauterine insemination on the pregnancy outcomes.

We know that washing the catheters are already washed in the case of embryo transfer for assisted reproductive techniques. Based on this knowledge, we also constituted the hypothesis which is about the impact of washing the catheter on the gametes and embryos. The pre-washing the catheter before intrauterine insemination may provide higher pregnancy results.


Eligibility criteria: Inclusion Criteria:

* at least 1-year infertility
* at least one patent fallopian tube confirmed by hysterosalpingography (HSG) or laparoscopy
* ovulatory menstrual cycles
* suitable semen analysis according to the World Health Organization (WHO) criteria for intrauterine insemination

Exclusion Criteria:

* bilateral tubal occlusion
* mild or severe endometriosis
* day 3 serum FSH (follicle-stimulating hormone) \> 13 IU/L
* abnormal thyroid function tests, hyperprolactinemia
* total motile sperm count (TMSC) \< 5 millions or severe teratospermia (\<4% normal forms) following semen preparation
* more than 3 follicles above the size of 17mm on the day of ovulation triggering

Primary outcomes:
measure: Clinical pregnancy rate
timeFrame: 8 weeks after intrauterine insemination
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05749159: New Physitherapy or Alternative Therapy for Hiccup
Official title: Comparison of New pHysIotherapy With Alternative Therapy for Clinical outComes in Patients With hiccUP: Rationale and Design of a Randomized Clinical Trail
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hiccup
Keywords: hiccup
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2023-03-01
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hiccup is a common symptom, and it is currently believed that hiccups result from diaphragmatic spasm, with onset ranging from minutes to days. Some patients may terminate on their own, or by ways such as gasping. For some patients with duration longer than 1 day, even longer than 2 days, medications may be needed, mainly: metoclopramide, eperisone hydrochloride tablets, etc. Acupuncture is also effective for some patients. Surgical treatment may be required for some clinically intractable hiccups. However, for the above interventions or treatment means, the current efficacy still needs to be improved.

In the previous clinical experience, we create a new physical clinic protocol which could terminate the hiccup symptom onset instantaneously without adding extra cost to the patient, and the physiotherapy method was convenient and effective. To further validate the superiority, safety of this novel physical therapy regimen, we designed a randomised controlled, prospective, single centre clinical study aimed at comparing the efficacy and safety of the novel physical therapy with conventional pharmacotherapy in patients with hiccups.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Able to swallow water

Exclusion Criteria:

* Allergy or contraindication to the following drugs: metoclopramide et al
* Severe choking on water and difficulty swallowing were present
* Impaired consciousness and inability to cooperate

Primary outcomes:
measure: the rate of termination of hiccup in 30 seconds
timeFrame: 1 year
measure: the time course from the start of therapy to the end of hicuup
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: 2nd Affiliated Hospital, School of Medicine, Zhejiang University
state: Zhejiang
Study officials:
affiliation: Second Affiliated Hospital, School of Medicine, Zhejiang University
name: Shen Jian
role: STUDY_CHAIR
References:
Clinical trial NCT02425059: Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms
Official title: Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms: Phase I and Phase II Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Rectal Neoplasms
Keywords: irreversible electroporation
Unresectable Rectal Neoplasms
Lead sponsor: Fuda Cancer Hospital, Guangzhou
Sponsor class: OTHER
First posted: 2015-04-23
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Rectal Neoplasms.

Detailed description: By enrolling patients with unresectable Rectal Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Rectal Neoplasms.

Eligibility criteria: Inclusion Criteria:

* Rectal Neoplasms diagnosed by positive biopsy or non-invasive criteria,
* Not suitable for surgical resection,
* Eastern Cooperative Oncology Group (ECOG) score of 0-1,
* A prothrombin time ratio \> 50%,
* Platelet count \> 80x10\^9/L,
* Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
* Able to comprehend and willing to sign the written informed consent form (ICF),
* Have a life expectancy of at least 3 months.

Exclusion Criteria:

* Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
* Any active implanted device (eg Pacemaker),
* Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
* Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
* Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.

Primary outcomes:
measure: Number of participants with Adverse events
timeFrame: 6 month
Secondary outcomes:
measure: Percentage of lesions that show no sign of recurrence 12 months after IRE
timeFrame: 12 months
Other outcomes:
measure: A minimum and maximum range of voltage for safe and effective IRE
timeFrame: 3 months
measure: Progress free disease (PFS)
timeFrame: 12 months
measure: Overall survival (OS)
timeFrame: 36 mouths
Locations:
city: Guangzhou
country: China
facility: Biological treatment center in Fuda cancer hospital
state: Guangdong
Study officials:
affiliation: Fuda Cancer Hospital
name: Lizhi Niu, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05291559: Acceptability and Efficacy of Enterade (VS001) in Children at Risk for Environmental Enteric Dysfunction in Bangladesh
Official title: Acceptability and Efficacy of Enterade (VS001) in Children at Risk for Environmental Enteric Dysfunction in Bangladesh
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Environmental Enteric Dysfunction
Lead sponsor: Virginia Commonwealth University
Sponsor class: OTHER
Collaborators: name: International Centre for Diarrhoeal Disease Research, Bangladesh
First posted: 2022-03-22
Enrollment: 20
Sex: ALL
Minimum age (years): 1
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a pilot study to assess the feasibility and acceptability of a trial of Enterade (VS001) to treat environmental enteric dysfunction in children from a low-income setting. Preliminary data on efficacy will also be obtained.

Detailed description: Primary Objectives

1. To determine tolerability of Enterade (VS001) in stunted Bangladeshi children between 1 and 2 years of age
2. To assess the efficacy of Enterade (VS001) in treatment of environmental enteric dysfunction by comparing improvements in 2-h lactulose mannitol ratio between Enterade (VS001) and a placebo.

Secondary Objectives

1. To assess the adherence to the regimen of 237ml (8 oz) of Enterade daily in children aged 1 to 2 years.
2. To assess Enterade (VS001) efficacy by comparing improvements in fecal measures of intestinal inflammation between Enterade (VS001) and placebo.

Eligibility criteria: Inclusion Criteria:

* Length-for-age Z score (LAZ) between -1 and -3 standard deviations
* Lactulose mannitol ratio \>0.09

Exclusion Criteria:

* Presence of known congenital or chronic diseases other than malnutrition
* Diarrhea (\> 3 unformed stools in a 24-hour window) in the 7 days prior to screening
* Anticipated unavailability for study visits
* A sibling previously enrolled in this study

Primary outcomes:
measure: Change in appetite
timeFrame: Baseline to 14 days
measure: Change in gastrointestinal health
timeFrame: Baseline to 14 days
measure: Change in 2 hour Lactulose mannitol ratio
timeFrame: Baseline to 14 days
Secondary outcomes:
measure: Residual intervention volume
timeFrame: 14 days
measure: Fecal lactoferrin
timeFrame: 14 days
measure: Fecal myeloperoxidase
timeFrame: 14 days
measure: Fecal neopterin
timeFrame: 14 days
measure: Fecal Reg 1 beta
timeFrame: 14 days
Other outcomes:
Locations:
city: Dhaka
country: Bangladesh
facility: International Centre for Diarrhoeal Disease Research, Bangladesh
Study officials:
affiliation: Virginia Commonwealth University
name: Jeffrey R Donowitz, MD
role: PRINCIPAL_INVESTIGATOR
References: